EyeCool TherapeuticsNovember 25, 2025EyeCool Therapeutics to Present at BTIG’s 5th Annual Ophthalmology Day
VenovaNovember 6, 2025Venova Medical Announces First Subjects Enrolled in VENOS-3 Pivotal IDE Study of the Velocity® Percutaneous AVF System
AtaCor MedicalOctober 9, 2025AtaCor Medical Secures $75M Financing to Support the Pivotal U.S. Study of its Extravascular ICD (EV-ICD) System
PanTher TherapeuticsSeptember 10, 2025PanTher Completes First Cohort in Pancreatic Cancer Phase 1b Trial Ahead of Expectations
EyeCool TherapeuticsSeptember 2, 2025EyeCool Therapeutics Appoints Dr. Vance Thompson to Board of Directors
EyeCool TherapeuticsAugust 7, 2025EyeCool Therapeutics Announces Promising Results from Double-Masked Randomized Controlled Trial in Chronic Ocular Surface Pain (COSP)
PanTher TherapeuticsJuly 8, 2025PanTher Initiates Phase 1b Clinical Trial of Absorbable, Long-Lasting, High-Dose Chemotherapy Patch for Pancreatic Cancer
AtaCor MedicalApril 29, 2024ATACOR MEDICAL CLOSES $28M SERIES C FINANCING TO DELIVER NEXT GENERATION EXTRAVASCULAR ICD AND PACING OPTIONS FOR CARDIAC RHYTHM MANAGEMENT
AtaCor MedicalNovember 3, 2022AtaCor Medical to Present Acute and 3 Month Results from Extravascular Implantable Cardioverter Defibrillator (EV-ICD) Studies
AtaCor MedicalApril 29, 2022AtaCor Medical to Present Preliminary Results from First-in-Human Extravascular Implantable Cardioverter Defibrillator (EV-ICD) Study
